Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management

BACKGROUND. Dysregulation of the phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway is implicated in human cancer growth and progression. Agents targeting this pathway are associated with hyperglycemia due to interaction with the insulin-glucose regu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Autores principales: Khan, Khurum H., Wong, Mabel, Rihawi, Karim, Bodla, Shankar, Morganstein, Daniel, Banerji, Udai, Molife, Lulama R.
Formato: Artigo
Lenguaje:Inglês
Publicado: AlphaMed Press 2016
Materias:
New Drug Development and Clinical Pharmacology
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4943382/
https://ncbi.nlm.nih.gov/pubmed/27151652
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0248
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares